<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055857</url>
  </required_header>
  <id_info>
    <org_study_id>7TMRINIID</org_study_id>
    <nct_id>NCT04055857</nct_id>
  </id_info>
  <brief_title>Structural and Functional Changes in Neuronal Intranuclear Inclusion Disease(NIID)</brief_title>
  <official_title>Structural and Functional Changes in Neuronal Intranuclear Inclusion Disease: A Pioneer Multi-modal 7T MRI Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University Interdisciplinary Institute of Neuroscience and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To discover the microstructure, macrostructure and functional changes with 7T multi-modal
      magnetic resonance imaging of Neuronal Intranuclear Inclusion Disease, and to explore new
      biomarkers for evaluating the severity and the progression of Neuronal Intranuclear Inclusion
      Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fractional anisotropy (FA)</measure>
    <time_frame>baseline</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean diffusivity (MD)</measure>
    <time_frame>baseline</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intracellular volume fraction(icvf)</measure>
    <time_frame>baseline</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>orientation dispersion index (ODI)</measure>
    <time_frame>baseline</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fiber number(fiber pass through the lesions)</measure>
    <time_frame>baseline</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fractional anisotropy (FA)</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean diffusivity (MD)</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intracellular volume fraction(icvf)</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>orientation dispersion index (ODI)</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fiber number(fiber pass through the lesions)</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters to describe integrity of white matter in diffusion MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>short-range and long-range functional connectivity around the lesions at rest</measure>
    <time_frame>baseline</time_frame>
    <description>Functional network connectivity impairments in patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>short-range and long-range functional connectivity around the lesions at rest</measure>
    <time_frame>6 months</time_frame>
    <description>Functional network connectivity impairments in patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neuronal Intranuclear Inclusion Disease</condition>
  <arm_group>
    <arm_group_label>NIID</arm_group_label>
    <description>NIID patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC</arm_group_label>
    <description>healthy control</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects enrolled in the study shall be selected from NIID patients who are diagnosed with
        skin biopsy and gene detection. The Investigator is responsible for screening potential
        subjects and selecting those who meet the eligibility criteria for the study as described.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with NIID

          2. Older than 18 years;

          3. Sign the informed consent form.

        Exclusion Criteria:

          1. The informed consent is withdrawn by the subject;

          2. Contraindications or intolerance to MRI: metallic foreign bodies, instability of vital
             signs, epilepsy, claustrophobia, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ruiliang Bai, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University Interdisciplinary Institute of Neuroscience and Technology (ZIINT)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hui Liang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University, School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui Liang, Doctor</last_name>
    <phone>18757139736</phone>
    <phone_ext>+86</phone_ext>
    <email>pushup@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daqiang Ke, Bachelor</last_name>
    <phone>15658173819</phone>
    <phone_ext>+86</phone_ext>
    <email>zhemuzhi@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Siemens 7T MR</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Xiong</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 11, 2019</last_update_submitted>
  <last_update_submitted_qc>August 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

